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Background: Dose intensive chemotherapy has not been tested prospectively for the treatment of gynecologic
sarcomas. We investigated the antitumor activity and toxicity of high-dose ifosfamide and doxorubicin, in the context
of a multidisciplinary strategy for the treatment of advanced and metastatic, not pretreated, gynecologic sarcomas.
Patients and methods: Thirty-nine patients were enrolled onto a phase I–II multicenter trial of ifosfamide, 10 g/m2
as a continuous infusion over 5 days, plus doxorubicin intravenously, 25 mg/m2/day for 3 days with Mesna and
granulocyte-colony-stimulating factor every 21 days. Salvage therapy was allowed after chemotherapy.
Results: Among the 37 evaluable patients, the tumor was locally advanced (n = 11), with concomitant distant
metastases (n = 5) or with distant metastases only (n = 21). After a median of three (range 1–7) chemotherapy cycles,
six patients experienced a complete response and 12 a partial response for an overall response rate of 49% (95% CI
32% to 66%). The response rate was higher in poorly differentiated tumors (62%) compared with moderately well
differentiated ones (18%), but was not different according to histology subtypes. Eleven patients had salvage therapy,
either immediately following chemotherapy (n = 7) or at time of progression (n = 4). With a median follow-up time of
5 years, the median overall survival was 30.5 months. Hematological toxicity was as expected neutropenia,
thrombopenia and anemia ‡grade 3 at 50%, 34% and 33% of cycles respectively. No toxic death occurred.
Conclusions: High-dose ifosfamide plus doxorubicin is an active regimen for all subtypes of gynecological
sarcomas. Its toxicity was manageable in a multicentric setting. The prolonged survival might be due to the
multidisciplinary strategy that was possible in one-third of the patients.
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introduction
Gynecologic sarcomas are a rare and heterogeneous group of
tumors accounting for only up to 5% of all female genital tract
malignancies. They include (i) pure sarcomas such as
leiomyosarcomas and endometrial stromal sarcomas, as well as
(ii) mixed sarcomas commonly referred to as mixed
mesodermal tumors or carcinosarcomas. Although tissue
cultures and immunohistological studies have suggested that
this latter group are metaplastic carcinomas rather than true
mixed tumors, and thus should be classified as sarcomatoid
carcinomas [1], all these subtypes are still characterized by
similar prognosis and recurrence patterns, involving high rates
of local regrowth and dissemination to the liver and the lungs,
suggesting a hematogenous spread [2].
Patients with recurrent disease are candidates for systemic
chemotherapy, although there is little evidence of cure [3].
Doxorubicin and ifosfamide are the most active single agents
offering variable response rates depending on histological tumor
types. Standard-dose doxorubicin has been shown to be more
active in leiomyosarcomas than in mixed mesodermal tumors,
while the reverse can be said for standard-dose ifosfamide [4–6].
Standard combined doses of doxorubicin and ifosfamide
yielded good anti-tumor activity in advanced or metastatic
leiomyosarcomas (response rate 30%) but showed no advantage
over single agents in terms of survival (median survival 6–12
months; long-term survivors <5%) [7]. Other combination
regimens, including cisplatin, darcabazine, etoposide,
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gemcitabine or taxanes, yielded similar results (median
survival £18 months) [8–10].
There is evidence for a dose–response relationship of
doxorubicin and 4-epidoxorubicin in advanced soft-tissue
sarcomas [11]. Several reports have suggested the same for
ifosfamide [12, 13]. Recently it was shown that relapse-free
survival may be improved when high-dose ifosfamide or
high-dose doxorubicin are used, although an effect on overall
survival was not demonstrated in those studies [14, 15].
No trials have yet been published for high-dose doxorubicin
combined with high-dose ifosfamide in the treatment of
gynecologic sarcomas. A pilot study based on incremental doses
of 4-epidoxorubicin and fixed high doses of ifosfamide in
advanced soft-tissue sarcomas yielded objective responses in
four of six patients with uterine sarcomas, which appeared to be
a dose-dependent effect as well [11].
In a multicenter phase I trial of advanced sarcomas,
including 12 gynecologic sarcomas, our study group
demonstrated that chemotherapy with high-dose doxorubicin
(up to 90 mg/m2) combined with high-dose ifosfamide
(10 g/m2) and supported by hematopoietic growth factors is
a feasible treatment option [16]. Although this regimen
involved severe myelosuppression, those events resolved
quickly. Encouraged by the high response rates obtained in
that study, our next step was to perform a regular phase II
trial of ifosfamide 10 g/m2 combined with doxorubicin at
75 mg/m2 in patients with advanced or metastatic gynecologic
sarcomas who had not previously received chemotherapy.
The purpose of this trial was to verify the high response rate
and to evaluate toxicity, time to progression and overall
survival, as well as the effect of salvage surgery on the
treatment outcomes.
Although multidisciplinary management with an essential
role for surgery has been widely accepted in the management
of primary soft tissue or gynecologic sarcoma [17], in
handling recurrent or metastatic disease, its place has not yet
been settled even though it is recognized as critical for the
outcome of some patients [3]. It has often been left to the
judgment of the investigators, and in the published
chemotherapy trials it has been either discouraged or not
reported. In the present trial, salvage therapy was allowed
whenever feasible after chemotherapy and should be
accounted for in the long-term results.
patients and methods
The trial protocol was in accordance with the Declaration of Helsinki
principles and was approved by the competent ethics commission. All
patients gave their written informed consent.
patient selection
Patients with histologically proven advanced or metastatic gynecologic
sarcoma were eligible for the trial. Tissue specimens were reviewed by an
independent group of pathologists (lead by G.J.) to confirm diagnosis and
differentiation scores.
Additional inclusion criteria were: measurable disease in one or two
dimensions as verified by physical examination or imaging techniques
(ascitis or pleural effusions were not considered measurable); ECOG
performance status £2; age 18–70 years; no previous chemotherapy;
no previous radiotherapy on the bladder; no CNS metastases; as
well as adequate hematological, renal, hepatic and cardiac (assessed by
echocardiography or multigated nuclear scanning) functions.
study design and treatment plan
This was a multicenter, non-randomized phase II trial conducted after
the completion of the phase I trial that identified the proper doses and
in which patients with gynecologic sarcomas had been treated. For the
phase II trial, ifosfamide was administered intravenously at a dose of
10 g/m2 as a continuous infusion over 5 days. Mesna was given
intravenously at a dose of 2 g/m2/day as a continuous infusion over 6 days.
Doxorubicin was administered intravenously at a dose of 25 mg/m2 as
a bolus for 3 days (total dose 75 mg/m2), starting 4 h after the beginning
of ifosfamide on day 1 of each 3-week cycle. Granulocyte colony
stimulating factor (G-CSF, Filgrastim) was administered once daily at
a dose of 5 lg/kg s.c., starting 24 h after the end of ifosfamide infusion
for a total of 10 days, or 14 days if the neutrophile count did not reach at
least 500/ll after 10 days. The ifosfamide and doxorubicin doses for 11
patients in the phase I trial were: ifosfamide 12 g/m2 and doxorubicin
50 mg/m2 (two patients), ifosfamide 10 g/m2 and doxorubicin 60 mg/m2
(two patients), ifosfamide 10 g/m2 and doxorubicin 75 mg/m2 (three
patients), ifosfamide 10 g/m2 and doxorubicin 90 mg/m2 (four patients).
Each chemotherapy cycle was given every 3 weeks. For this report those
11 patients were pooled together with the patients included in the
phase II trial. Indeed, when analyzed separately for all major end points,
the results of both trials were comparable.
Salvage therapy with surgery and/or radiotherapy aiming at removing all
residual tumor tissue was performed in all patients who were considered to
potentially benefit from such an approach, either immediately following
chemotherapy or at the time of progression.
response, toxicity assessment, dose modification
All tumors were evaluated based on standard WHO criteria to assess
response to chemotherapy [18] and responses had to be confirmed at least
4 weeks later. CT scans were obtained at baseline, after every other
chemotherapy cycle and at the end of treatment. Up to three uni- or
bi-dimension measurable lesions had to be documented.
Toxicity was assessed based on WHO grading. Cardiotoxicity was
monitored by assessing cardiac ejection fraction every two to three cycles
and prior to each cycle exceeding doxorubicin cumulative doses of <450 mg/
m2. Chemotherapy was discontinued if cardiac ejection fraction dropped
to <40% and was not administered in the presence of serum creatinine
>150 lmol/l or creatinine clearance <60 ml/min.
Neurotoxicity was assessed based on M. D. Anderson scores [19]. On
obtaining scores of ‡2, an attempt was made not to decrease the dose of
ifosfamide. Any neurotoxicity was managed by administering methylene
blue as an intravenous bolus of 50 mg repeated at the same dose every 2 h
until the neurotoxic event resolved, or as continuous infusion at 200 mg/day
diluted in 5% dextrose [20].
Drug administration was delayed by 1 or 2 weeks if white blood cell count
was <3500/ll or platelet count was <100 000/ll at day 22. When treatment
with intravenous antibiotics was necessary, or when bleeding due to
thrombocytopenia occurred, the total dose of ifosfamide could be decreased
from 10 to 8 g/m2. In the case of normal recovery from myelosuppression
and if no febrile episodes requiring administration of intravenous
antibiotics occurred, ifosfamide dose could be increased up to a total dose of
12 g/m2 during subsequent cycles. Doxorubicin dose could be decreased
from 75 to 60 mg/m2 in case of WHO mucositis grade 3 or higher. In the
absence of mucositis, it was proposed to increase the dose of doxorubicin
to 30 mg/m2/day for a total of 90 mg/m2.
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statistical methods
The primary end point was the tumor response rate (WHO criteria). The
Simon’s optimal two-stage design was used to calculate sample size for the
phase II trial. The treatment would be considered uninteresting if the
response rate were less than 50% and promising if the response rate were at
least 70%. For a significance level of 5% and a power of 80%, a total of 43
patients was needed with 15 patients in stage I and a further 28 patients in
stage II. Based on the evaluation of the first 15 patients, it was decided to
continue the trial up to the planned target number of 43 patients. However,
the trial was closed after including 27 patients due to low accrual. It was
planned to analyze the data from this phase II trial together with those from
phase I, for which the results were published in 1998 by our group [16], in
order to preserve the statistical power of 80% to detect a promising response,
instead of 63% if only 27 patients had been included in the analysis.
Confidence intervals for response rates were calculated by the Clopper–
Pearson method. Time to progression was calculated for all patients from
registration to the day of evidence of progressive disease or death, with
censoring at last follow-up. Survival time was calculated from registration to
death or last follow-up evaluation and was analyzed using the Kaplan–Meier
method. Differences in survival were tested by the log-rank test. Exploratory
multivariate analysis of survival using Cox regression was also performed.
Variables represented by appropriate binary indicators were the following:
histology (leiomyosarcoma versus other), differentiation (poorly
differentiated versus other), response (CR/PR versus other), tumor location
(presence of distant metastases versus loco-regional alone) and salvage
therapy (yes versus no).
results
patients characteristics
Between March 1993 and June 1999, 39 patients from six SAKK
(Swiss Group for Clinical Cancer Research) centers with
advanced gynecologic sarcomas were enrolled: 12 in the phase I
and 27 in the phase II study. Two patients were not evaluable
and were excluded from analysis: one patient in phase I never
started treatment due to a rapidly worsening performance
status and died 1 month after enrollment; another patient in
phase II presented with an undifferentiated carcinoma, which
was only detected after histopathological review and showed
a complete remission upon six cycles of treatment.
Characteristics of the 37 evaluable patients are shown in Table 1.
The median age of the patients was 53 years and ranged from
34 to 69 years. They had a good performance status, with ECOG
performance status 0 or 1 in 92% of cases. The tumor was
confined to the pelvis and to the local lymph nodes in 11
patients and with concomitant distant metastases in five
patients. Twenty-one patients had only distant metastases,
mainly within the lung (n = 18), and some as distant lymph
nodes (n = 11), liver metastases (n = 5) or peritoneal seeding
(n = 4). Other tumor locations were infrequent, with pleura,
bone and pancreas in one patient each.
Confirmed by the pathology reviews, the most common
diagnosis was leiomyosarcomas in 25 patients. Endometrial
stromal sarcoma and mixed mesodermal tumors were
diagnosed in five patients each. One patient had a rhabdoid
tumor of the pudendal great lip with lymph node metastasis and
another had a pleomorphic spindle cell sarcoma of the uterus.
The tumor was classified according to the differentiation status.
Seventy per cent had poorly differentiated and 30% moderately
or well differentiated tumors.
toxicity profile and dose intensity
A total of 130 chemotherapy cycles were analyzed for toxicity. A
median of three (range 1–7) chemotherapy cycles were
administered per patient. As expected, myelosuppression was
the predominant type of toxicity. Severe neutropenia of WHO
‡grade 3 was observed in half of the cycles and 73% of patients,
and developed into febrile neutropenia in 29% of cycles with
proven infection in 23%. No toxic death occurred.
Thrombocytopenia and anemia of WHO ‡grade 3 were found
in 34% and 33% of cycles, respectively, and involved more than
half of the patients.
Neurological toxicity of grade 1 according to the M. D.
Anderson score was observed during 10 cycles and of grade 2 or
higher in four cycles; all were manageable by methylene blue
administration and/or stopping ifosfamide. No severe renal
toxicity was noted, but transient microscopic hematuria was
observed during 15 cycles with minimal creatinine elevation in
four of them. Mucositis occurred in 45% of cycles but was
moderate, except in 12 cycles with WHO grade 3. No clinical
cardiac failure was reported. Cardiac ejection fractions
measured repeatedly in 28 patients did not show any relevant
decrease, except for one patient in which it dropped from
62% to 48%.
Doses were modified in 28% of cycles because of toxicity. A
total of 27% chemotherapy cycles were delayed because of
toxicity or because the patients so requested. However, the
median dose intensity (calculated in mg/m2/week) could be
Table 1. Patients characteristics
Number of patients 37
Age (years)
Median (range) 53 (34–69)
ECOG performance status
0 2
1 12
2 3
Histologic diagnosis
Leiomyosarcoma (LMS) 25
Endometrial stromal sarcoma (ESS) 5
Mixed Mullerian tumor (MMT) 5
Othera 2
Histologic grade
Well differentiated 6
Moderately differentiated 5
Poorly differentiated 26
Tumor location
Loco-regional 11
Loco-regional and distant 5
Distant 21
Lung 18
Lymph node 11
Liver 5
Peritoneum 4
Pleura 1
Bone 1
Pancreas 1
aMalignant rhabdoid tumor and pleomorphic spindle cell sarcoma.
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maintained at ‡75% of the planned dose for ifosfamide and at
‡88% for the planned dose of doxorubicin. Dose escalation in
either drug has never been performed in any patient.
response to chemotherapy and survival
Responses were assessed in all 37 patients. Six patients (16%)
showed a complete response to chemotherapy and 12 (32%)
experienced a partial remission, resulting in an overall response
rate of 49% (95% CI 32% to 66%). Eleven patients (30%)
had stable disease and eight (21%) progressive disease.
Stratified by histology, the overall response rate was 12 of 25
(48%) for patients with leiomyosarcomas, two of five (40%)
for patients with endometrial stromal sarcomas and three of
five (60%) for patients with mixed Mullerian tumors. The
response rate was higher in poorly differentiated tumors (16 of
26 = 62%, 95% CI 41% to 80%) than in well or moderately
differentiated ones (2 of 11 = 18%, 95% CI 2% to 52%).
With a median follow-up time of 5 years, 22 patients have
progressed and 18 have died of their disease. The median time to
progression was 27.7 months (95% CI 8.9–45.9) and the median
overall survival was 30.5 months (95% CI 15.7 to upper limit
not reached) (Figure 1).
In seven patients, chemotherapy was immediately followed by
salvage therapy aimed at removing all residual disease (surgery,
n = 4; surgery and radiotherapy, n = 2; radiotherapy, n = 1).
In four more patients, salvage surgery was performed at the time
of progression. These 11 patients included eight responders to
chemotherapy. Additional palliative treatment was applied in 16
patients (chemotherapy, n = 14; radiotherapy, n = 2) at the time
of disease progression.
Salvage therapy improved survival, with 64% of the
patients surviving at 5 years (95% CI 41% to 99%) and the
median survival time not yet reached. For patients in whom it
was not possible to perform major surgery and/or radiotherapy,
the median survival remained at 15.7 months (95% CI
12.1–44.8) (Figure 2), with 18% survival at 5 years (95% CI
6% to 50%). Multivariate analysis confirmed that salvage
therapy was a significant prognostic factor for better
outcomes (hazard ratio 0.19, 95% CI 0.05–0.73). Distant
metastasis, by contrast, was an unfavorable prognostic factor
(hazard ratio 7.29, 95% CI 1.03–51.5).
discussion
The present trial demonstrated that high-dose ifosfamide in
combination with doxorubicin and hematopoietic growth
factors, is an effective treatment modality for the treatment of
advanced and metastatic gynecologic sarcomas. In our patient
population it yielded a high response rate of 49%. Compared
with the uninteresting response rate of 50% and the
promising response rate of 70% considered in the trial design,
this observed activity was, however, at the lower end of the
expected response rate. Moreover, the data of the 26 and 11
patients from the phase II and I studies had to be pooled to
increase the statistical power to 80% with a 5% significance
level. The poorly differentiated tumor in our trial had the
highest response. The response rate was 48% in
leiomyosarcoma, 40% in endometrial stromal sarcoma and
60% in mixed mesodermal. Only a few active agents are
known to be effective in the treatment of gynecologic
sarcomas [10]. A 30% response rate has been reported for
standard-dose ifosfamide plus doxorubicin in leiomyosarcomas
[7]. A 19% response rate was obtained with doxorubicin plus
cyclophosphamide in mixed mesodermal tumors [21].
Ifosfamide 7.5 g/m2 administered as a single agent over 5 days
yielded response rates of 32%–36% in mixed mesodermal
tumors, 17% in leiomyosarcomas and 33% in endometrial
stromal sarcomas [4, 5, 22]. In metastatic endometrial
carcinoma, the addition of hormonal therapy to chemotherapy
might be beneficial [23]. The most active regimen has
combined gemcitabine and docetaxel. It has produced a 45%
response rate in 29 uterine leiomyosarcomas, half of them
having received previous anthracyclines [9]. Up to now, no
prospective studies have been available on dose-intensive
chemotherapies for gynecologic sarcomas. Only one report
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Figure 1. Kaplan–Meier curve for overall survival (broken line: 95% CI).
0.0
0.2
0.4
0.6
0.8
1.0
0 12 24 36 48 60 72
Salvage  therapy
No salvage therapy
Pr
op
or
tio
n 
su
rv
ivi
ng
Months
Number at risk (salvage / no salvage therapy):
11 11 10 9 7 5 3
26 12 7 4 3 3 1
Figure 2. Overall survival of patients subjected to salvage therapy aimed
at eliminating all residual disease after chemotherapy, compared with
patients receiving chemotherapy only.
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indicated a high response rate of 67% in six patients treated with
ifosfamide 9 g/m2 plus epidoxorubicin 100–140 mg/m2 [11].
Myelosuppression was the anticipated toxicity. Although dose
modifications or treatment delays due to toxicity were necessary
in 28% and 27% of the cycles, respectively, the dose intensity
could be maintained at 75% of the planned dose for ifosfamide
and almost 90% for doxorubicin. WHO ‡3 neutropenia was
reported in 49% of the cycles, thrombopenia in 34% and anemia
in 33%. There was no patient death that could be attributed
to toxicity and this might also explain the good results of the
study. This toxicity profile was not different from similar
single-agent or combination regimen for the treatment of
sarcomas, even if in some studies the doses were much lower
than ours and not supported by hematopoietic growth factors
[24, 25]. Myelosuppression was thus severe with febrile
neutropenia in a third of the cycles, but should probably be
accepted as inherent to these combination regimens [26] and
should be administered only in experienced centers. Transient
neurological and renal toxicities were infrequent. Clinical heart
failure was not observed.
While the overall survival times obtained in previous studies
usually ranged from 6 to a maximum of 18 months [10], our
prolonged median follow-up period of 5 years strikingly
revealed a median survival time of 30 months. Most of the
available data on high-dose ifosfamide and doxorubicin were
collected in adult patients with soft-tissue sarcomas [16, 27–29].
Some trials suggested a dose–effect relationship; however, their
results concerning the effect of high-dose ifosfamide and
doxorubicin on survival remain controversial.
In our trial, the Cox multivariate analysis suggested that
salvage treatment with the intention to remove all residual
disease had a major positive prognostic influence. Indeed, the
patients who did not receive any treatment except
chemotherapy had a median overall survival of 15.7 months and
a 5-year survival rate of 18%, while the selected patients for
whom complementary therapy was judged possible had a 5-year
survival rate of 65%. The concept of multidisciplinary
management, with an essential role being reserved for surgical
intervention, has been widely accepted for soft-tissue or
gynecologic primary sarcomas [17]. The precise role of such
strategies in handling recurrent or metastatic disease remains to
be defined, even though they are known to make a critical
difference in some patients [3]. In the published chemotherapy
trials, the use of salvage treatment modalities was either
discouraged, not reported or left to the investigators’ discretion
[30]. In the present trial, 29% of patients were subjected to
surgery. Previous phase II chemotherapy trials in soft-tissue
sarcomas have included similar percentages of surgical
intervention. In accordance with our own results, those
subgroups reached extended survival times of 30–39 months
after complete resection of liver or lung metastases [31, 32].
Likewise, salvage surgery for pulmonary or extra-pulmonary
recurrences of uterine leiomyosarcoma increased the median
overall survival to 3.9 years irrespective of the site of
recurrences [33, 34].
These improved outcomes in patients undergoing salvage
treatments after chemotherapy might conceivably be due mainly
to a patient selection bias. The true benefit of surgery needs
further clarification in prospective studies.
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